Tagitanlimab Improves Upon Chemo in Recurrent, Metastatic Nasopharyngeal Cancer
Adding tagitanlimab to treatment with gemcitabine and cisplatin (GP) can improve progression‑free survival (PFS) in patients with recurrent or metastatic nasopharyngeal cancer.
A phase 3 trial (NCT05294172) assessed tagitanlimab plus gemcitabine and cisplatin versus placebo plus the same chemotherapy in treatment‑naïve patients with recurrent or metastatic nasopharyngeal cancer. Median progression‑free survival was not reached in the tagitanlimab‑GP arm compared with 7.9 months in the placebo‑GP arm (HR 0.47; 95% CI 0.33‑0.66; P < 0.0001). Overall survival data are immature, but a trend toward benefit was observed. The regimen showed high objective‑response rates (81.7% vs 74.5%) and acceptable safety.
If confirmed, tagitanlimab could become the first‑line standard of care for recurrent or metastatic nasopharyngeal cancer—a disease with limited effective options and poor survival outcomes.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research
- The Clinical Trial Landscape for Melanoma Therapies